RHEUMATOLOGY

The WILLOW trial reveals Enpatoran’s strong performance in mucocutaneous lupus, achieving high CLASI-50 and CLASI-70 response rates, remission milestones, and rapid IFN gene suppression in both CLE and SLE patients.

Women aged 35–44 with lupus face a 50x higher heart attack risk—often in the first year. This shows early CV threats in SLE and the need for dual protection: disease control (DORIS/LLDAS) + traditional risk factor management. #LupusAwareness #HeartHealth